Taysha Gene Therapies Announces Incentive Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, May 3, 2024 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on the development and commercialization of AAV-based gene therapies for the treatment of serious monogenic diseases of the central nervous system (CNS), today announced that the Compensation Committee of the Board of Directors of Taysha on May 1, 2024, granted a total of four new employees options to purchase 528,000 common shares of the company in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as incentive materials for those individuals who join Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $2.42 per share, which is equal to the closing price of Taysha common stock on the date of grant. The stock option has a term of ten years and vests over a four-year period, with 25% of the option vesting on the first anniversary of the vesting start date and the remaining 75% of the option vesting in equal monthly periods. installments during the subsequent 36 months. . Vesting of the stock option is contingent on the employee continuing to work for Taysha on each vesting date.

About Taysha gene therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for serious monogenic diseases of the central nervous system. The lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic cause of the disease. With a particular focus on developing transformative medicines, Taysha aims to address serious unmet medical needs and dramatically improve the lives of patients and their caregivers. The company’s management team has proven experience in the development and commercialization of gene therapy. Taysha leverages this experience, manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to quickly translate treatments from the bench to the bedside. For more information, please visit http://www.tayshagtx.com.

Company contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
[email protected]

Media contact:
Carolyn Hawley
Inizio calls
[email protected]